Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 3/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GRK6 | P43250 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22725388 | 0.85 | KAT2B (0.57) | KAT2BTSHRCYP3A4MEN1KMT2A | |
| SCHEMBL15322458 | 0.83 | TDP1 (0.51) | KAT2BMEN1KMT2AMAPTMAPK1 | |
| SCHEMBL981242 | 0.82 | KAT2B (0.64) | KAT2BTSHRCYP3A4MAPTMAPK1 | |
| SCHEMBL17678174 | 0.81 | MEN1 (0.46) | KAT2BCYP3A4MEN1KMT2AMAPT | |
| SCHEMBL7466967 | 0.81 | KAT2B (0.71) | KAT2BTSHRCYP3A4MAPTGRK6 | |
| SCHEMBL3636228 | 0.79 | KAT2B (0.69) | KAT2BTSHRCYP3A4MAPTALDH1A1 | |
| SCHEMBL15082923 | 0.78 | MAPT (0.61) | KAT2BTSHRCYP3A4MAPTMAPK1 | |
| SCHEMBL20337732 | 0.78 | KAT2B (0.49) | KAT2BMEN1KMT2AMAPTMAPK1 | |
| SCHEMBL14338942 | 0.77 | ALDH1A1 (0.50) | TSHRCYP3A4MEN1KMT2AMAPT | |
| SCHEMBL977454 | 0.77 | KAT2B (0.57) | KAT2BMEN1KMT2AMAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10040767-B2 | Benzimidazole derivatives and uses thereof | PELOTON THERAPEUTICS, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-20170088523-A1 | BENZIMIDAZOLE DERIVATIVES AND USES THEREOF | PELOTON THERAPEUTICS, INC. | 2017-03-30 | — | — | US | disclosed |
| WO-2015175845-A1 | BENZIMIDAZOLE DERIVATIVES AND USES THEREOF | PELOTON THERAPEUTICS, INC. (US) | 2015-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170088523-A1 | BENZIMIDAZOLE DERIVATIVES AND USES THEREOF | ACSS2, GLS2, ACSL3 | KAT2B 575/4885TSHR 4507/4885CYP3A4 1408/4885 |
| US-10040767-B2 | Benzimidazole derivatives and uses thereof | ACSS2, GLS2, ACSL3 | KAT2B 575/4885TSHR 4507/4885CYP3A4 1408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.